ReSPECT-GBM: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) (clinicaltrials.gov) - Mar 26, 2025 - P1/2 | N=55 | Recruiting | Sponsor: Plus Therapeutics | Trial completion date: Jan 2025 ➔ Dec 2025 | Trial primary completion date: Jan 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|